Enovis Corporation (ENOV)

Enovis Corp.'s stock price has declined significantly, falling approximately 38.6% to 38.73% over the past year, hitting a 52-week low in January 2026. A substantial net loss in Q3 2025, due to a non-cash goodwill impairment charge of $548 million, impacted the stock. While first-quarter 2025 revenues met expectations, management lowered its full-year Adjusted EPS guidance. In November 2025, the Principal Accounting Officer acquired 2,468 shares, indicating insider confidence.

Information regarding specific demand seasonality for Enovis Corp.'s products and services was not explicitly available in the provided search results.

Enovis Corp. is a medical technology company specializing in orthopedic solutions, operating in the Healthcare sector and Medical Devices industry. The company is divided into two segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment offers products like orthopedic bracing, therapy equipment, and physical therapy products. The Reconstructive segment provides surgical implant products and tools. Enovis distributes its products through independent distributors and directly, operating under brands such as DJO. Formerly known as Colfax Corporation, it transitioned to a pure-play medical technology company in 2022.

Enovis Corp. has a global presence, operating in the United States and internationally. Its brands are sold in over 50 countries through subsidiaries or distributors. The company has facilities across Europe, Asia, South America, and the Middle East. Its global headquarters are in Wilmington, Delaware, U.S.

Enovis Corporation is described as an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions. The company operates under well-regarded brands such as ESAB and DJO. Financial challenges, such as the significant net loss in Q3 2025 due to a goodwill impairment charge, primarily impacted investor sentiment and stock performance rather than directly affecting public brand perception.

Enovis Corp.'s ownership is heavily weighted towards institutional investors, who control a significant majority of the company's outstanding shares. As of the third quarter of 2025, institutional investors held approximately 98.45% of the common stock. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and American Century Companies Inc. BDT Capital Partners LLC is the largest individual shareholder, owning 67.57 million shares, representing 118.16% of the company. Steven M. Rales is also listed as an insider owner.